Relay Therapeutics (RLAY) Preferred Stock Liabilities (2019 - 2020)
Relay Therapeutics' (RLAY) quarterly Preferred Stock Liabilities came in at $537.8 million in Q2 2020, little changed on a QoQ basis from $537.8 million in Q4 2019.
Relay Therapeutics (RLAY) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Relay Therapeutics (RLAY) has 2 years of Preferred Stock Liabilities data on file, last reported at $537.8 million in Q2 2020.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $537.8 million in Q2 2020; TTM through Jun 2020 was $537.8 million, a N/A change from a year earlier, with the FY2019 full-year figure at $537.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2020 stood at $537.8 million, roughly flat from $537.8 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for RLAY reached as high as $537.8 million in Q4 2019 and fell as low as $537.8 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Relay Therapeutics | 3.43 Bn | 3.43 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 537.78 Mn |
| Dec 31, 2019 | 537.78 Mn |